| Autor: |
Moormeier, Jill A., Williams, Stephanie F., Kaminer, Lynne S., Garner, Miriam, Bitran, Jacob D. |
| Zdroj: |
JNCI: Journal of the National Cancer Institute; 1/6/1990, Vol. 82 Issue 1, p29-34, 6p |
| Abstrakt: |
Forty patients with refractory solid tumors or non-Hodgkin's lymphoma were treated with high-dose cyclophosphamide, thiotepa, and carmustine (BCNU), followed by autologous stem cell rescue, in a phase I does escalation study. The dose-limiting toxic effect was delayed drug-induced pulmonary disease, seen in three patients who received 660–750mg of BCNU/min combination with cyclophosphamide and thitepa. The early death rate due to toxic effects was 20%; all deaths were attributed to sepsis or respiratory failure. The overall response rate was 63%. The median time to disease progression was 14 weeks. Although this regimen provided effective cytoreduction, its use in heavily pretreated patients with bulky disease is of limited value. [J Natl Cancer Inst 82:29–34,1990] [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
